References

1. Trauma Infectious Diseases Outcomes Study Group: Department of Defense Technical Report - Invasive Fungal Infection Case Investigation. Bethesda, MD: Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences; April 11, 2011.
2. Warkentien T, Rodriguez C, Lloyd B, Wells J, Weintrob A, Dunne J, et al. Invasive mold infections following combat-related injuries. Clin Infect Dis 2012; 55(11): 1441-49.
3. Weintrob AC, Weisbrod AB, Dunne JR, Rodriguez CJ, Malone D, Lloyd BA, et al. Combat trauma-associated invasive fungal wound infections: epidemiology and clinical classification. Epidemiol Infect 2015; 143(1): 214-24.
4. Tribble DR, Rodriguez CJ, Weintrob AC, Infectious Disease Clinical Research Program Trauma Infectious Disease Outcomes Study Group, et al. Environmental factors related to fungal wound contamination after combat trauma in Afghanistan, 2009-2011. Emerg Infect Dis. 2015 Oct;21(10):1759-69.
5. Hospenthal DR, Chung KK, Lairet K, et al. Saksenaea erythrospora infection following combat trauma. J Clin Microbiol 2011; 49(10): 3707-9.
6. Kronen R, Liang SY, Bochicchio G, Bochicchio K, Powderly WG, Spec A. Invasive fungal infections secondary to traumatic injury. Int J Infect Dis. 2017 Sep;62:102-111.
7. Paolino KM, Henry JA, Hospenthal DR, Wortmann GW, Hartzell JD. Invasive fungal infections following combat-related injury. Mil Med 2012; 177(6): 681-5.
8. Evriviades D, Jeffery S, Cubison T, Lawton G, Gill M, Mortiboy D. Shaping the military wound: issues surrounding the reconstruction of injured servicemen at the Royal Centre for Defence Medicine. Philos Trans R Soc Lond B Biol Sci 2011; 366(1562): 219-30.
9. Tribble DR, Ganesan A, Rodriguez CJ. Combat trauma-related invasive fungal wound infections. Curr Fungal Infect Rep. 2020 Jun;14(2):186-196.
10. Fares Y, El-Zaatari M, Fares J, Bedrosian N, Yared N. Trauma-related infections due to cluster munitions. J Infect Public Health 2013; 6(6): 482-86.
11. Tully CC, Romanelli AM, Sutton DA, Wickes BL, Hospenthal DR. Fatal Actinomucor elegans var. kuwaitiensis infection following combat trauma. J Clin Microbiol 2009; 47(10): 3394-9.
12. Rodriguez RCJ, Ganesan A, Shaikh F, Carson ML, Bradley W, Warkentien TE, Tribble DR. Combat-related invasive fungal wound infections. Mil Med. 2022 May 4;187(Suppl 2):34-41.
13. Mende K, Stewart L, Shaikh F, Bradley W, Lu D, Krauss MR, Greenberg L, Yu Q, Blyth DM, Whitman TJ, Petfield JL, Tribble DR. Microbiology of combat-related extremity wounds: Trauma Infectious Disease Outcomes Study. Diagn Microbiol Infect Dis. 2019 Jun;94(2):173-179.
14. Warkentien TE, Shaikh F, Weintrob AC, et al. Impact of Mucorales and other invasive molds on clinical outcomes of polymicrobial traumatic wound infections. J Clin Microbiol 2015; 53(7): 2262-70.
15. Ganesan A, Shaikh F, Bradley W, et al. Disease Clinical Research Program Trauma Infectious Disease Outcomes Study Group. Classification of trauma-associated invasive fungal infections to support wound treatment decisions. Emerg Infect Dis. 2019 Sep;25(9):1639–47.
16. Lewandowski LR, Weintrob AC, Tribble DR, et al. Early complications and outcomes in combat injury related invasive fungal wound infections: a case-control analysis. J Orthop Trauma 2016; 30(3).
17. Horvath EE, Murray CK, Vaughan GM, et al. Fungal wound infection (not colonization) is independently associated with mortality in burn patients. Annals of surgery. 2007 Jun;245(6):978.
18. Pruitt BA Jr, McManus AT, Kim SH, Goodwin CW. Burn wound infections: current status. World J Surg. 1998 Feb;22(2):135-45.
19. Ganesan A, Wells J, Shaikh F, et al. Molecular detection of filamentous fungi in formalin-fixed paraffin-embedded specimens in invasive fungal wound infections is feasible with high specificity. J Clin Microbiol. 2019 Dec 23;58(1):e01259-19.
20. Rodriguez C, Weintrob AC, Shah J, et al. Risk factors associated with invasive fungal Infections in combat trauma. Surg Infect (Larchmt) 2014; 15(5): 521-26.
21. Lewandowski L, Purcell R, Fleming M, Gordon WT. The use of dilute Dakin's solution for the treatment of angioinvasive fungal infection in the combat wounded: a case series. Mil Med 2013; 178(4): e503-07.
22. Barsoumian A, Sanchez CJ, Mende K, et al. In vitro toxicity and activity of Dakin's solution, mafenide acetate, and amphotericin B on filamentous fungi and human cells. J Orthop Trauma 2013; 27(8): 428-36.
23. Jaber D, Younes N, Khalil E, et al. Effect of diluted Dakin's solution versus standard care on diabetic foot ulcer management: a randomized controlled trial. J Am Podiatr Med Assoc. 2022 Mar 16;112(1):20-213.
24. Barsoumian A, Sanchez CJ, Mende K, et al. In vitro toxicity and activity of Dakin's solution, mafenide acetate, and amphotericin B on filamentous fungi and human cells. J Orthop Trauma. 2013 Aug;27(8):428-36
25. Vick LR, Propst RC, Bozeman R, Wysocki AB. Effect of Dakin's solution on components of a dermal equivalent. J Surg Res 2009; 155(1): 54-64.
26. Irish J, Carter DA, Hokohi T, et al. Honey has an antifungal effect against Candida species Medical Mycology, Volume 44, Issue 3, May 2006, Pages 289–291,
27. Anand S., Deighton M., Livanos G. et al. Agastache honey has superior antifungal activity in comparison with important commercial honeys. Sci Rep 9, 18197 (2019).
28. Tashkandi H. Honey in wound healing: an updated review. Open Life Sci. 2021 Oct 6;16(1):1091-1100.
29. Barret JP, Ramzy PI, Heggers JP, Villareal C, Herndon DN, Desai MH. Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents. Burns. 1999 Sep 1;25(6):505-8.
30. Kheirabadi BS, Mace JE, Terrazas IB, et al. Safety evaluation of new hemostatic agents, smectite granules, and kaolin-coated gauze in a vascular injury wound model in swine. J Trauma 2010; 68(2): 269-78.
31. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Jr., Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48(12): 1743-51.
32. Meletiadis J, Antachopoulos C, Stergiopoulou T, et al. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother 2007; 51(9): 3329-37.
33. Neofytos D, Lombardi LR, Shields RK, Ostrander D, Warren L, Nguyen MH, Thompson CB, Marr KA. Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis. 2012 Apr;54(7):913-21.
34. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci 2010; 99(8): 3291-301.
35. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50(1): 126-33.
36. Krishna G, Ma L, Martinho M, O'Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201.
37. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42(7): e61-5.
38. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014 May;69(5):1162-76.
39. Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol 2015; 8(3): 321-34.
40. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul;16(7):828-837.
41. Rodriguez CJ, Weintrob AC, Dunne JR, et al. Clinical relevance of mold culture positivity with and without recurrent wound necrosis following combat-related injuries. J Trauma Acute Care Surg 2014; 77(5): 769-73.